Eris Lifesciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ERIS BSE: 540596

₹1191.90

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #34 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Eris Lifesciences Limited (this stock)	16,517	84.7	16.6%	-26.6%	0.60%	51	12	8

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹18,568 Cr

EV / EBITDA

30.8x

EV / Sales

11.01x

Market cap / Sales

9.79x

Earnings yield

1.18%

Quarterly Financials

Download CSV

Standalone Consolidated

↓ Negative

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 470 Cr, down 21.8% YoY.

↓ Negative

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 48 Cr, down 51.7% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	444	64	48	₹3.4900
March 31, 2026	277	-33	-9	₹-0.6300
Dec. 31, 2025	315	4	3	₹0.2300
Sept. 30, 2025	650	235	150	₹10.9800
June 30, 2025	579	156	100	₹7.3400
March 31, 2025	405	41	30	₹2.2400
Dec. 31, 2024	400	6	2	₹0.1310
Sept. 30, 2024	429	46	28	₹2.0600
June 30, 2024	457	27	17	₹1.2500
March 31, 2024	341	42	40	₹2.9000
Dec. 31, 2023	324	35	32	₹2.3300
Sept. 30, 2023	410	120	118	₹8.6600
June 30, 2023	411	133	111	₹8.1400

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	470	304	340	674	601	422	408	442	462	362	328	417	415
Operating revenue	444	277	315	650	579	405	400	429	457	341	324	410	411
Other income	26	27	25	24	23	17	8	14	5	20	3	7	4
Operating expenses	324	256	238	354	362	284	300	294	333	262	250	265	256
Operating profit	120	22	77	297	216	121	100	135	123	79	74	144	156
Operating profit margin	27.0%	7.9%	24.5%	45.6%	37.4%	29.9%	24.9%	31.4%	27.0%	23.3%	22.9%	35.3%	37.8%
Depreciation	40	39	39	39	38	43	47	46	46	29	28	25	20
Interest	42	43	45	46	45	53	55	56	56	29	15	7	7
Exceptional items, gain / (loss)	—	—	-15	—	—	—	—	—	—	—	—	—	—
Profit before tax	64	-33	4	235	156	41	6	46	27	42	35	120	133
Tax	16	-24	1	85	56	11	4	18	10	2	3	2	22
Net profit	48	—	3	150	100	30	2	28	17	40	32	118	111
EPS	3.49	-0.63	0.23	10.98	7.34	2.24	0.13	2.06	1.25	2.90	2.33	8.66	8.14
Net profit (TTM)	—	—	283	282	160	77	86	116	206	300	348	416	413
EPS (TTM)	14.07	17.92	20.79	20.69	11.77	5.68	6.34	8.54	15.14	22.03	25.59	30.57	30.38

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,822	362	244
March 31, 2025	1,698	120	77
March 31, 2024	1,487	329	300
March 31, 2023	1,331	437	398

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
Total income (before exceptional items)	12.5%	11.4%	1,920^†	1,741^†	1,522^†	1,348^†	1,245^†	1,119^†	1,035^†	929^†	789^†
Operating revenue	11.0%	10.4%	1,822	1,698	1,487	1,331	1,216^†	1,109^†	1,020^†	897^†	761^†
Other income	—	—	98^†	43^†	35^†	17^†	29^†	10^†	15^†	32^†	28^†
Operating expenses	—	—	1,209^†	1,211^†	1,033^†	826^†	732^†	692^†	665^†	563^†	—
Operating profit	6.6%	8.0%	612^†	487^†	454^†	505^†	484^†	417^†	356^†	334^†	—
Operating profit margin	—	—	33.6%^†	28.7%^†	30.5%^†	38.0%^†	39.8%^†	37.6%^†	34.9%^†	37.2%^†	—
Depreciation	—	—	154^†	182^†	102^†	65^†	51^†	38^†	45^†	32^†	22^†
Interest	—	—	180^†	220^†	57^†	21^†	3^†	1^†	2^†	23^†	—
Exceptional items, gain / (loss)	—	—	-15^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	-6.1%	-1.4%	362	120	329	437	459^†	389^†	324^†	312^†	312^†
Tax	—	—	118^†	43^†	29^†	39^†	41^†	38^†	32^†	26^†	18^†
Net profit	-15.0%	-7.0%	244	77	300	398	417^†	351^†	291^†	285^†	294^†
EPS	-15.1%	-7.0%	17.92^†	5.68^†	22.03^†	29.27^†	30.71^†	25.82^†	21.22^†	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
Operating margin	33.6%^†	28.7%^†	30.5%^†	38.0%^†	39.8%^†	37.6%^†	34.9%^†	37.2%^†	—
EBIT margin	29.7%^†	20.0%^†	26.0%^†	34.4%^†	38.0%^†	35.1%^†	31.9%^†	37.3%^†	—
PBT margin	19.9%	7.1%	22.1%	32.8%	37.7%^†	35.1%^†	31.7%^†	34.8%^†	41.0%^†
Net margin	13.4%	4.6%	20.2%	29.9%	34.3%^†	31.6%^†	28.5%^†	31.8%^†	38.6%^†
Interest coverage	3.02x^†	1.55x^†	6.73x^†	22.00x^†	154.31x^†	500.86x^†	175.54x^†	14.68x^†	—
Dividend payout	0.0%^†	129.4%^†	0.0%^†	25.1%^†	19.6%^†	21.3%^†	13.5%^†	—	—
Earnings retention	100.0%^†	-29.4%^†	100.0%^†	74.9%^†	80.4%^†	78.7%^†	86.5%^†	—	—
Current ratio	0.60x	0.63x	—	—	—	—	—	—	—
Quick ratio	0.52x	0.44x	—	—	—	—	—	—	—
Debt to equity	0.65x	0.88x	—	—	—	—	—	—	—
Return on equity	7.6%	3.1%	—	—	—	—	—	—	—
Return on assets	4.2%	1.5%	—	—	—	—	—	—	—
Return on capital employed	13.3%^†	8.0%^†	—	—	—	—	—	—	—
Asset turnover	0.32x	0.33x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	564	-694	71	49	515
March 31, 2025	702	-359	-310	8	694
March 31, 2024	336	-2,492	2,160	349	-13
March 31, 2023	322	-513	194	311	11
March 31, 2022	369	-268	-88	53	316

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	5,778	3,195	3,182	1,278	798	1,023	1,718	25	124	121
March 31, 2025	5,222	2,515	2,501	580	1,633	628	994	84	107	191
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.